Lean Ways To Develop Medicines
Landmark BioVentures AG (LBV), founded in 2021 and headquartered in Basel, Switzerland, is an integrated and agile biotech hub-and-spoke company.
LBV takes a unique model focused on lean operations, smart capital allocation, and diversified yet complementary nexus of 7 companies developing 10 first-in-class therapeutics.
Landmark BioVentures Unique Model
Nexus of New Biotech Ventures
Founders & Partners
Zaki Sellam
CEO
• 20+ years of experience in Biotech
• Expert in Immuno-Oncology Drug Development
• Involved in multiple start-ups & more than 40 Deals
• Strong CRO and Academic network
• Board Member of Swiss Healthcare Licensing Group & Basel BioValley Association
Gary Brandam
COO
-
12+ years of experience in Biotech and Pharma
-
Led development of 4 program in oncology start-ups
-
Strong expertise in l commercialization of Oncology and Rare Disease assets
-
Expert in launch excellence in oncology and rare disease
Jacques Bauer, PhD
CDO
-
35+ years of experience in Biopharma
-
Scientist, medicinal chemist and biologist
-
Former R&D Director at OM Pharma
-
Expert in drug discovery, drug development in oncology, immunology and metabolic diseases
-
Strong expertise in intellectual property
Mehdi Chelbi
CBO
-
20+ years of experience in in Biotech, Pharma and CROs
-
Entrepreneur and C-Level positions
-
Expert in corporate development and fundraising
-
Strong expertise in Preclinical and clinical development execution
-
Involved in the design, planning and setup of 300+ trials
Samson Fung, MD
CMO
-
30+ years of experience in Biotech and Pharma
-
Physician by training in oncology and hematology
-
Former CEO of Volvox Therapeutics
-
Expert in clinical development, medical affairs market access
-
Spent 15+ years in pharma including Roche, Novartis, Novo Nordisk and Astra Zeneca
Bernouillistrasse 20
Basel CH-4056
Switzerland